In 2025, I invested as an angel through the Ada Angels program, backing pre-seed companies in Denmark aligned with Ada Ventures’ thesis on healthy aging, climate equity, and economic empowerment.
Portfolio Companies
Healper
🌐https://healper.dk
Marketplace connecting psychologists/therapists to patients.
Sourced through another angel in the Ada program.
Why I invested: This was my first deal under the angel program. Helper, in its earliest stages, generated strong revenue and quickly became the dominant marketplace for mental health professionals in Denmark by securing contracts with Danish insurance companies. Shortly after the investment, the company began its expansion plan to the UK. This investment was made in 2024.
InterHuman AI
InterHuman AI builds APIs that enable artificial intelligence systems to understand and respond to human social signals, improving empathy, communication, and interaction quality in AI-driven products. The company is research-backed, with technology spun out of the Technical University of Denmark (DTU). Founder Paula Petco has since built a commercial team to lead InterHuman AI’s growth and market adoption.
Sourced at Antler Demo Day in Copenhagen.
Why I invested: As AI becomes embedded in everyday life, social intelligence will be a defining differentiator. InterHuman is building foundational infrastructure for emotionally and socially aware AI, a layer that most teams underestimate but users immediately feel. The Interhuman AI Read more on the Interhuman AI investment here: https://tech.eu/2025/08/25/interhuman-ai-raises-2m-to-build-the-social-intelligence-layer-for-ai/
Alcolase
Alcolase develops a patented enzyme-based product that helps people metabolize alcohol more efficiently—similar in concept to Lactaid—reducing the negative physical effects associated with alcohol intolerance. In East Asia, alcohol intolerance affects an estimated 30–50% of the population, highlighting the scale of the unmet need the product addresses.
Sourced at TechBBQ in Copenhagen
Why I invested: Beyond being impressed with founder and CEO Mikkel, Alcolase is addressing a widely overlooked problem in East Asia. The company has the potential to create an entirely new market—similar to how lactase enabled the rise of lactose-free products. In parallel, Alcolase is exploring the use of its enzyme technology as a novel, low-energy approach to producing alcohol-free beverages, an alternative to today’s energy-intensive methods. This positions Alcolase as a platform company that can both improve health outcomes in East Asia and scale alongside global wellness trends and growing consumer demand for alcohol-free products.
Monix Health
Continuous hormone medical device company providing real-time insights into women’s hormonal health. First patent-pending non-invasive device similar to GLP-1 devices used by diabetic patients. The company has an initial focus on with an initial focus on IVF, then menopause, and other hormone-related issues.
Sourced through a biotech email newsletter
Why I invested:
Hormonal health is one of the most under-instrumented areas of medicine despite its outsized impact on women’s quality of life. Monix combines strong scientific grounding with a product vision that could redefine how we monitor and manage metabolic and reproductive health at scale.
SymbioMatch
SymbioMatch helps replace chemical fertilizers with biology. The company combines AI with one of the largest collections of soil samples from across Europe to understand how different microbes help crops grow in different environments. Using this data, SymbioMatch creates customized biofertilizers tailored to specific soils and crops—reducing pollution, restoring soil health, and cutting emissions tied to energy-intensive fertilizer production. This approach addresses climate impact at the foundation of the food system.
Sourced through another angel in the Ada program.
Why I invested:
Founder Dr. Marcela Mendoza-Suárez brings rare depth at the intersection of soil science and applied innovation. During her research, she integrated one of the largest collections of soil samples across Europe, creating a powerful foundation of real-world data. With the emergence of AI, SymbioMatch can now understand soil biology at a much deeper level and rapidly translate those insights into customized biofertilizers for farmers. The company is already generating revenue through paid pilot programs, demonstrating both technical credibility and clear market demand. This combination of scientific defensibility, data advantage, and early commercial traction made SymbioMatch a compelling investment.
What I Learned
- I entered the program planning to invest exclusively in software, drawing on my background as a software engineer. Instead, shaped by Denmark’s startup landscape and my own curiosity, I unexpectedly became a biotech investor.
- I didn’t expect how much value I’d be able to add for founders, from warm introductions to my investor network to thoughtful feedback on strategy and positioning.
- I enjoyed working closely with the other angels, learning from their feedback on deals and having the opportunity to co-invest alongside them.
Whats Next
After 18 months in the Ada program, I’ve built strong momentum and am now receiving high-quality inbound opportunities from other investors. I’m eager to work with funds aligned with my emerging thesis to continue supporting European founders with both capital and meaningful connections.
Thank You
I’m deeply grateful to the entire Ada team for creating such a thoughtful and impactful program. Special thanks to Jasmin, Check Matt, Michael, Diarra, Emily, and Xun—each of you has been incredibly supportive, generous with your time, and instrumental in shaping this experience.
I’m also thankful for my peers in the Ada Angels cohort—Carl Johan, Katja, Kathya, Ana, Char, Phaedria, and Ellen. I truly enjoyed collaborating with you, learning from your perspectives, and co-investing alongside such a thoughtful and engaged group. I would eagerly jump at the opportunity to work with you again in this capacity.
Discover more from Hadiyah Mujhid
Subscribe to get the latest posts sent to your email.
Hadiyah Mujhid 